1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Germany

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: Germany
GERMANY 1
HEALTHCARE SYSTEM 1
Facts and Figures 1
Market Indicators 2
Provision and Funding 4
Statutory Health Insurance 4
Private Health Insurance 5
Healthcare Services 5
Healthcare Reform 5
PRICING 6
Prescription Drugs 6
Early Benefit Assessments 6
Rebate Negotiations Following Early Benefit Assessments 9
Market Developments 11
Mandatory Rebates 11
Voluntary Discount Agreements 12
Generic Drugs 13
Mandatory Discounts 13
Voluntary Discount Agreements 14
Hospital Drugs 15
Pricing 15
Purchasing 15
Dispensing to Out-patients 16
OTC Drugs 16
Discounts 16
REIMBURSEMENT 16
Admission to Reimbursement 16
Non-prescription Drugs 17
Lifestyle Drugs 17
Minor Illnesses 17
Unproven Therapeutic Benefit, Medical Necessity or Economic Efficiency 18
Therapeutic Recommendations 18
Off-label Drugs 19
Negative List 19
Reimbursement Categories 19
Reimbursement Prices 19
Reference Price System 19
Hospital Reimbursement 21
Formularies 21
Funding 21
Changes in Reimbursement Status 22
Changes in Reimbursement Prices 22
Price Moratorium 22
Impact of Early Benefit Assessments 23
Reference Price Revisions 23
Germany, Pharmaceutical Pricing and Reimbursement Concise Guide
v
Maximum Reimbursement Prices 24
PHARMACOECONOMICS 24
Pharmacoeconomic Requirements 24
Early Benefit Assessments 24
Benefit Assessments 25
Cost-benefit Assessments 26
PRICE BUILD UP 27
Wholesalers 27
Margins 27
Discounts 27
Direct Distribution 27
Unit-dose Products 28
Background 28
Retail Pharmacies 28
Prescription Drugs 28
Non-Prescription Drugs 29
Parallel Import Quota 30
Background 30
Dispensing Doctors 31
Sales Tax 31
COST CONTAINMENT 31
Industry Paybacks 31
Promotional Costs 31
Advertising 31
Payments to Physicians 32
Patient Co-payments 32
GKV 32
PKV 33
Prescribing Controls 34
Binding Prescribing Guidelines 34
Prescribing Conditions for Drugs Subject to Early Benefit Assessments 34
Regional Prescribing Agreements 34
Disease Management Programmes 35
Prescribing Software 36
Generics 36
Generic Substitution 37
Biosimilars 38
Rx-to-OTC Switches 39
Process 39
Recent Switches 39
OTC Market 39
Parallel Trade 40
Parallel Imports 40
Parallel Exports 40
FUTURE DEVELOPMENTS 40
Outlook 40
Germany, Pharmaceutical Pricing and Reimbursement Concise Guide
vi
Pricing Reforms Pending 40
Biosimilars Savings Potential 41
Parallel Import Dispensing Quota Controversy 41
NAMES and ADDRESSES 41

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the UK

  • January 2017
    19 pages
  • Therapy  

  • United Kingdom  

View report >

Biological Therapy Industry in the US

  • January 2017
    9 pages
  • Vaccine  

  • United States  

View report >

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Related Market Segments :

Therapy
Pharmaceutical
Health Insurance

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.